Viking Therapeutics (NASDAQ: VKTX)
Viking Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Viking Therapeutics Company Info
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
News & Analysis
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Shares of the clinical-stage biotech have skyrocketed on recent good news.
Is it Too Late to Buy Viking Therapeutics Stock?
Viking Therapeutics stock is on fire following a successful phase 2 trial for its obesity care candidate.
Viking Therapeutics Just Announced More Positive Results: Time to Buy?
The drugmaker isn't losing momentum.
1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now
Its long-term growth potential looks like it's improving, again.
Could Viking Therapeutics Stock Be a Millionaire Maker?
There is a plausible path for this biotech stock to make some investors millionaires.
Viking Therapeutics Stock Has 72% Upside, According to 1 Wall Street Analyst
The company's experimental new weight-management drug looks great so far.
Is It Too Late to Buy Viking Therapeutics Stock?
Shares of Viking Therapeutics have skyrocketed more than 350% this year.
Valuation
Earnings Transcripts
Viking Therapeutics (VKTX) Q2 2022 Earnings Call Transcript
VKTX earnings call for the period ending June 30, 2022.
Viking Therapeutics (VKTX) Q1 2022 Earnings Call Transcript
VKTX earnings call for the period ending March 31, 2022.
Viking Therapeutics (VKTX) Q4 2021 Earnings Call Transcript
VKTX earnings call for the period ending December 31, 2021.
Viking Therapeutics (VKTX) Q3 2021 Earnings Call Transcript
VKTX earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.